Estimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center (TRODUMCRA)

December 10, 2025 updated by: Centre Hospitalier Universitaire de Nīmes

People in Administrative Detention Centers often come from areas of medium or high HIV, hepatitis C & B endemic, and are often unaware of their serological status. Currently, HIV, hepatitis C & B screening is not systematically performed at the CRA of Nîmes, and when performed, serological tests are used. The main disadvantage of this method is the length of time it takes to obtain the results, with subjects frequently discharged before receiving their results.

To improve the care of these vulnerable persons, the aim of this study is to estimate the prevalence of HIV, hepatitis C and hepatitis B in the detainees of the administrative detention center of Nîmes, by systematically screening with a rapid diagnosis test. In case of a positive rapid diagnosis test test, a serology test will confirm the rapid diagnosis test result.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

350

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Nîmes, France
        • CHU Nimes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Study Population

All detainees arriving at the Administrative Detention Center of Nîmes from Monday to Friday, and those arriving over the weekend if still present by Monday.

Description

Inclusion Criteria:

  • The patient must have given their free and informed oral consent
  • Patient detained in the Nîmes Administrative Detention Center

Exclusion Criterion

• It is impossible to give the subject informed information

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Detainees in an Administrative Detention Center
Diagnostic test: Rapid diagnosis test against HIV and hepatitis C and B
combined Insti VIH® + Toyo VHC®, then First response Ag Hbs tested on capillary blood sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of HIV infection in detainees at the Nîmes Administrative Detention Center
Time Frame: Inclusion
Rapid diagnosis test: Positive/negative
Inclusion
Prevalence of Hepatitis C infection in detainees at the Nîmes Administrative Detention Center
Time Frame: Inclusion
Rapid diagnosis test: Positive/negative
Inclusion
Prevalence of Hepatitis B infection in detainees at the Nîmes Administrative Detention Center
Time Frame: Inclusion
Rapid diagnosis test: Positive/negative
Inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of co-infections between HIV, Hepatitis C and Hepatitis B
Time Frame: Inclusion
Yes or no for co-infection (HIV-Hep C / HIV-Hep B / HepC-HepB / Hiv-HepC-HepB)
Inclusion
Participant country of origin
Time Frame: Inclusion
Country name
Inclusion
Knowledge of HIV, Hep C and Hep B status
Time Frame: Inclusion
Yes/no
Inclusion
Participant previous transfusion
Time Frame: Inclusion
Yes/no
Inclusion
Intravenous drug use
Time Frame: Inclusion
Yes/no
Inclusion
Intranasal drug use
Time Frame: Inclusion
Yes/no
Inclusion
Shared drug paraphernalia
Time Frame: Inclusion
Yes/no
Inclusion
Non-protected sexual activity
Time Frame: Inclusion
Yes/no
Inclusion
Participant with piercings
Time Frame: Inclusion
If yes, professional done or not
Inclusion
Participant with tattoos
Time Frame: Inclusion
If yes, professional done or not
Inclusion
Feasibility of screening
Time Frame: End of study (1 year)
% of subjects with available samples (ie no subject refusal, subjects arriving at weekend or holiday, study not offered on a weekday, technical problem with test interpretation)
End of study (1 year)
Acceptability of the screening
Time Frame: End of study (1 year)
% of subjects giving samples
End of study (1 year)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire de Nīmes

Investigators

  • Principal Investigator: Mélanie Kinne, Centre Hospitalier Universitaire de Nîmes

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 8, 2022

Primary Completion (Actual)

December 7, 2022

Study Completion (Actual)

December 7, 2022

Study Registration Dates

First Submitted

November 12, 2021

First Submitted That Met QC Criteria

November 12, 2021

First Posted (Actual)

November 19, 2021

Study Record Updates

Last Update Posted (Estimated)

December 18, 2025

Last Update Submitted That Met QC Criteria

December 10, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIMAO/2020-2/MK-1
  • 2021-A00544-37 (Other Identifier: ANSM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe